Avalo Therapeutics, Inc. (AVTX)

Market Cap	12.03M
Revenue (ttm)	1.92M
Net Income (ttm)	-31.54M
Shares Out	1.03M
EPS (ttm)	-114.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,161
Open	11.68
Previous Close	12.01
Day's Range	11.50 - 13.02
52-Week Range	3.95 - 1,130.40
Beta	1.17
Analysts	Buy
Price Target	107.50 (+824.33%)
Earnings Date	May 2, 2024

About AVTX

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also devel...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2015
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: AVTX

Financial Performance

In 2023, AVTX's revenue was $1.92 million, a decrease of -89.34% compared to the previous year's $18.05 million. Losses were -$31.54 million, -24.28% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for AVTX stock is "Buy." The 12-month stock price forecast is $107.5, which is an increase of 824.33% from the latest price.

Price Target

$107.5

(824.33% upside)

Analyst Consensus: Buy